Related Experiment Videos
Kinin-enhancing drugs for unexplained subfertility in men
P Vandekerckhove1, R Lilford, A Vail
1Institute of Epidemiology, University of Leeds, 34 Hyde Terrace, Leeds, Yorkshire, UK, LS2 9LN. patrickv@epid.leeds.ac.uk
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Kallikrein treatment for male infertility may not improve pregnancy rates in men with idiopathic oligo-astheno-teratospermia. Further research is needed to confirm its effects on sperm parameters and fertility outcomes.
Area of Science:
- Reproductive Medicine
- Urology
- Endocrinology
Background:
- Idiopathic oligo-astheno-teratospermia is a common cause of male infertility.
- Kallikrein, a kinin-releasing enzyme, has been investigated for its potential to improve semen quality.
- The kinin system is present in the male reproductive tract and may influence sperm function.
Purpose of the Study:
- To evaluate the efficacy of drugs enhancing kinin levels in increasing pregnancy rates for couples with male factor infertility.
- To assess the secondary effects of such treatments on sperm parameters and sex hormones.
Main Methods:
- A systematic search of controlled trials was conducted.
- Sixteen randomized controlled trials (RCTs) involving treatments like clomiphene citrate and tamoxifen were identified.
- Data on pregnancy rates, semen parameters (concentration, motility, morphology), and hormone levels (FSH, testosterone, estradiol) were analyzed.
Main Results:
- The provided abstract does not contain specific results regarding pregnancy rates or changes in sperm parameters and hormone levels.
- Further details on the outcomes of the included RCTs are necessary to draw conclusions.
Conclusions:
- The effectiveness of kallikrein or other kinin-level-enhancing drugs in improving pregnancy rates for idiopathic oligo-astheno-teratospermia remains uncertain.
- More robust evidence is required to establish the role of these treatments in male infertility management.